Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
This study aims to investigate the treatment of refractory or relapsed DLBCL with orelabrutinib and gemox. The primary endpoint is response rate (complete response rate and overall response rate), and the second endpoints are survival time (OS and PFS) and toxicities.
DLBCL
DRUG: Orelabrutinib and Gemox
Overall response rate, overall response rate after treated by Orelabrutin and Gemox, 12 weeks after the initiation of the treatment
Progression Free Survival (PFS), PFS was defined as time from study registration to first disease progression or death whichever occurred first, otherwise subject data were censored at time last known disease free, Up to two years after the start of the study|Overall Survival (OS), OS was defined as time from study registration to death, and otherwise censored at time last known alive, Up to two years after the start of the study|Duration of Response（DOR）, The time from the first assessment of CR or PR to PD (progressive disease) or death from any cause, Up to three years after the start of the study|Adverse events, All the adverse events of the patients related will be assessed and graded by NCI CTCAE v5.0, Up to one year after the start of the study
This study aims to investigate the treatment of refractory or relapsed DLBCL with orelabrutinib and gemox. The primary endpoint is response rate (complete response rate and overall response rate), and the second endpoints are survival time (OS and PFS) and toxicities.